Austin D Williams1, Kyle K Payne2, Avery D Posey3,4, Christine Hill5, Jose Conejo-Garcia5, Carl H June3,4, Julia Tchou1. 1. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10th floor South, Philadelphia, PA 19104, USA. 2. The Wistar Institute, Philadelphia, PA, USA. 3. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Perelman School of Medicine, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. 5. Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Abstract
PURPOSE OF REVIEW: The breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed researchers to harness the immune system with novel immunotherapy strategies, many of which have shown promise in breast cancer. This review discusses the application of immunotherapy to the treatment of breast cancer. RECENT FINDINGS: Both basic science and clinical trial data are rapidly developing in the use of immunotherapy for breast cancer. The current clinical trial landscape includes therapeutic vaccines, immune checkpoint blockade, antibodies, cytokines, and adoptive cell therapy. SUMMARY: Despite early failures, the application of immunotherapeutic strategies to the treatment of breast cancer holds promise.
PURPOSE OF REVIEW: The breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed researchers to harness the immune system with novel immunotherapy strategies, many of which have shown promise in breast cancer. This review discusses the application of immunotherapy to the treatment of breast cancer. RECENT FINDINGS: Both basic science and clinical trial data are rapidly developing in the use of immunotherapy for breast cancer. The current clinical trial landscape includes therapeutic vaccines, immune checkpoint blockade, antibodies, cytokines, and adoptive cell therapy. SUMMARY: Despite early failures, the application of immunotherapeutic strategies to the treatment of breast cancer holds promise.
Entities:
Keywords:
Breast cancer; Cancer vaccines; Chimeric antigen receptor T cells (CAR T); Immune checkpoint; Immunotherapy; Oncolytic viruses
Authors: Anupama Sharma; Ursula Koldovsky; Shuwen Xu; Rosemarie Mick; Robert Roses; Elizabeth Fitzpatrick; Susan Weinstein; Harvey Nisenbaum; Bruce L Levine; Kevin Fox; Paul Zhang; Gary Koski; Brian J Czerniecki Journal: Cancer Date: 2012-01-17 Impact factor: 6.860
Authors: C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero Journal: Cancer Immunol Immunother Date: 2008-04-30 Impact factor: 6.968
Authors: Ketil A Camilio; Meng-Yu Wang; Brynjar Mauseth; Stein Waagene; Gunnar Kvalheim; Øystein Rekdal; Baldur Sveinbjørnsson; Gunhild M Mælandsmo Journal: Breast Cancer Res Date: 2019-01-22 Impact factor: 6.466
Authors: Alaa Alnefaie; Sarah Albogami; Yousif Asiri; Tanveer Ahmad; Saqer S Alotaibi; Mohammad M Al-Sanea; Hisham Althobaiti Journal: Front Bioeng Biotechnol Date: 2022-06-22
Authors: Stephen Iwanowycz; Soo Ngoi; Yingqi Li; Megan Hill; Christopher Koivisto; Melodie Parrish; Beichu Guo; Zihai Li; Bei Liu Journal: JCI Insight Date: 2021-09-08